MARKET

PEN

PEN

Penumbra Inc
NYSE

Real-time Quotes | Nasdaq Last Sale

149.38
+7.46
+5.26%
After Hours: 149.38 0 0.00% 16:02 05/27 EDT
OPEN
143.54
PREV CLOSE
141.92
HIGH
149.43
LOW
142.26
VOLUME
223.34K
TURNOVER
0
52 WEEK HIGH
293.20
52 WEEK LOW
130.96
MARKET CAP
5.63B
P/E (TTM)
-855.5556
1D
5D
1M
3M
1Y
5Y
Is Penumbra, Inc. (NYSE:PEN) Popular Amongst Insiders?
If you want to know who really controls Penumbra, Inc. ( NYSE:PEN ), then you'll have to look at the makeup of its...
Simply Wall St. · 05/12 17:28
Penumbra's Return on Invested Capital Insights
Pulled from Benzinga Pro data, Penumbra (NYSE:PEN) posted Q1 earnings of $79.00 thousand, an increase from Q4 of 100.32%. Sales dropped to $203.90 million, a 0.06% decrease between quarters.
Benzinga · 05/12 14:16
Despite Seeing Accelerated 2023 Growth, This Analyst Cut Penumbra's Price Target - Here's Why
Benzinga · 05/04 19:54
What 4 Analyst Ratings Have To Say About Penumbra
Analysts have provided the following ratings for Penumbra (NYSE:PEN) within the last quarter:
Benzinga · 05/04 13:21
--Wells Fargo Adjusts Penumbra's Price Target to $265 from $321, Keeps Overweight Rating
MT Newswires · 05/04 12:24
Penumbra (PEN) Reports Q1 Loss, Tops Revenue Estimates
Penumbra (PEN) delivered earnings and revenue surprises of -116.67% and 4.03%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/03 22:15
Penumbra: Q1 Earnings Insights
Penumbra (NYSE:PEN) reported its Q1 earnings results on Tuesday, May 3, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings Penumbra missed estimated earnings by 116.67%, reporting an EPS of $-0.01 versus an estimate of $0...
Benzinga · 05/03 21:41
Penumbra Q1 GAAP EPS $0.00 vs $0.32 In Same Qtr. Last Year, Adj. Net Loss $2.261M vs Net Income $13.463M In Same Qtr. Last Year, Sales $203.90M Beat $195.04M Estimate
Penumbra (NYSE:PEN) reported quarterly sales of $203.90 million which beat the analyst consensus estimate of $195.04 million by 4.54 percent. This is a 20.51 percent increase over sales of $169.20 million the same
Benzinga · 05/03 20:57
More
No Data
Learn about the latest financial forecast of PEN. Analyze the recent business situations of Penumbra Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 9 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

44.44%Strong Buy
44.44%Buy
11.11%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average PEN stock price target is 248.50 with a high estimate of 272.00 and a low estimate of 220.00.
High272.00
Average248.50
Low220.00
Current 149.38
EPS
Actual
Estimate
0.030.090.150.21
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 371
Institutional Holdings: 32.94M
% Owned: 87.43%
Shares Outstanding: 37.68M
TypeInstitutionsShares
Increased
109
1.36M
New
38
67.56K
Decreased
80
661.19K
Sold Out
41
205.19K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
+1.86%
Healthcare Equipment & Supplies
+2.75%
Key Executives
Chairman/President/Chief Executive Officer/Director
Adam Elsesser
Chief Financial Officer
Maggie Yuen
Executive Vice President/General Counsel/Secretary
Johanna Roberts
Chief Accounting Officer
Lambert Shiu
Director
Arani Bose
Independent Director
Harpreet Grewal
Independent Director
Don Kassing
Independent Director
Janet Leeds
Independent Director
Bridget O'rourke
Independent Director
Surbhi Sarna
Independent Director
Thomas Wilder
No Data
No Data
About PEN
Penumbra, Inc. is a global healthcare company. The Company is engaged in the design, development, manufacturing, and marketing of medical devices. It is focused on developing and building its portfolio of products, including its thrombectomy, embolization and access technologies. The Company's neuro products include Thrombectomy, Embolization, Neurovascular access, Neurosurgical Tools, and Virtual Reality Platform. Its Vascular products include Thrombectomy and Embolization. The principal specialist physicians and healthcare providers in its two target end markets include Neuro: Interventional neuroradiologists, neurosurgeons, interventional neurologists, occupational therapists, physical therapists, and physiatrists; Vascular: Interventional radiologists, vascular surgeons, and interventional cardiologists. The common vascular and neurovascular diseases the Company focuses on are Ischemic Stroke, Brain Aneurysm, Hemorrhagic Stroke, Venous Thromboembolism, and Acute Coronary Syndrome.

Webull offers kinds of Penumbra Inc stock information, including NYSE:PEN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PEN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PEN stock methods without spending real money on the virtual paper trading platform.